Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
131.21
+0.49 (+0.37%)
Streaming Delayed Price
Updated: 3:56 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Dow Jones Skyrockets To Record Heights, Shatters 37,000 Mark, Fueled By Fed's Dovish Stance
December 13, 2023
The 30 largest blue-chip stocks in the Dow Jones Industrial Average surged to unprecedented highs following the Federal Reserve's decision to keep interest rates steady.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
What's Going On With Moderna Stock Today?
December 12, 2023
Moderna Inc (NASDAQ: MRNA) announced changes to its operating model to bring focus to its short- and
Via
Benzinga
Why Is C4 Therapeutics (CCCC) Stock Up 72% Today?
December 12, 2023
C4 Therapeutics stock is rising higher on Tuesday as investors in CCCC shares celebrate a new collaboration agreement with Merck.
Via
InvestorPlace
Why Is Cancer-Focused C4 Therapeutics Stock Soaring Today?
December 12, 2023
C4 Therapeutics Inc (NASDAQ: CCCC) has entered into an exclusive license and collaboration agreement with Merck & Co Inc (NYSE: MRK) to develop degrader-antibody conjugates (DACs), an emerging modality...
Via
Benzinga
(MRK) - Analyzing Merck & Co's Short Interest
December 04, 2023
Via
Benzinga
Price Over Earnings Overview: Merck & Co
November 30, 2023
Via
Benzinga
Analyst Ratings for Merck & Co
November 29, 2023
Via
Benzinga
Looking Into Merck & Co's Recent Short Interest
November 10, 2023
Via
Benzinga
Biotech Is Coming Back, Can The Run Last?
December 11, 2023
The rally can be attributed to lower interest rates and seasonal factors from the end of Q4 through January. But recently some major biopharmaceutical deals have supported the rally.
Via
Talk Markets
Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer
December 08, 2023
Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) announced that the Phase 3 LEAP-001 trial of Keytruda (pembrolizu
Via
Benzinga
Double Flops For Merck's Lung Cancer Studies
December 07, 2023
Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non-small cell lung cancer (NSCLC)...
Via
Benzinga
5 Dividend Stocks That Recently Increased Their Payouts
December 06, 2023
One stock increased its dividend by 25%.
Via
The Motley Fool
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments
December 02, 2023
LianBio received a $465 million buyout offer from Tang Capital Management. In addition, Tang also offered shareholders a contingent value right for 80% of net proceeds from any license or divestment of...
Via
Talk Markets
PFAS's Forever Problem: Ohio Lawsuit Against Chemical Companies Fizzles Out
November 28, 2023
Big chemical companies won a lawsuit preventing 11.8 million Ohio residents from suing them for PFAS chemicals in their blood.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
Merck & Co Inc (NYSE: MRK) released results from the STRIDE-3 Phase 3 trial evaluating V116, the company's investigational 21-valent
Via
Benzinga
Biotech And Healthcare Portfolio Playbook For December 2023/24
November 27, 2023
We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January.
Via
Talk Markets
Stability Seekers: 7 Low-Volatility Stocks for Uncertain Times
November 23, 2023
Although it might seem too conservative, low-volatility stocks should be on your radar to prepare for the unknown.
Via
InvestorPlace
Merck's Caraway Deal: Analyst Says "Timely, Anchored By Novel Programs & Management Team"
November 22, 2023
BMO Capital Markets analyst Evan David Seigerman reiterated an Outperform rating on Merck & Company, Inc. (NYSE: MRK),
Via
Benzinga
Three Solid Stocks That Still Have Plenty Of Growth Left
November 20, 2023
The key ingredient is to find companies with sound fundamentals that aren’t appreciated as they should be. More so if their long-term growth is not fully accounted for.
Via
Talk Markets
Merck's Latest Drug For Chronic Cough Faces FDA Pushback
November 18, 2023
A panel of advisors to the Food and Drug Administration (FDA) reportedly expressed concerns about the efficacy of Merck & Company, Inc.'s (NYSE:
Via
Benzinga
Exposures
Product Safety
FDA Approves Merck's Blockbuster Cancer Drug For Type Of Gastric Cancer
November 17, 2023
The FDA has approved Merck & Co Inc's (NYSE: MRK) Keytruda, an anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with...
Via
Benzinga
Exposures
Product Safety
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
November 17, 2023
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Senator's Bearish Tesla Bet Under Scrutiny As He Buys Put Options Ahead Of Elon Musk-Led Company's Q3 Results That Set Stock Slide In Motion
November 17, 2023
Sen. Tommy Tuberville bought 3 tranches of put options to sell Tesla shares at $190 a day ahead of Q3 results that set in motion a stock slump.
Via
Benzinga
Merck's Gefapixant Under FDA Lens: Advisory Committee To Discuss Chronic Cough Drug's Future
November 16, 2023
The FDA's Pulmonary-Allergy Drugs Advisory Committee
Via
Benzinga
Exposures
Product Safety
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
The FDA approved Bristol Myers Squibb And Co's (NYSE: BMY) Augtyro (repotrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small
Via
Benzinga
Exposures
Product Safety
2 Healthcare Stocks That Could Make You Richer
November 15, 2023
Merck and Intuitive Surgical both still have bright futures ahead.
Via
The Motley Fool
The 3 Best Defensive Stocks for Uncertain Times
November 13, 2023
These are the best defensive stocks to buy as they represent low beta names and companies with robust fundamentals and cash flows.
Via
InvestorPlace
Merck and Bristol Myers Squibb Will Face Off in This 1 Market -- but Who Will Win?
November 11, 2023
There's a lot more at stake than bragging rights.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
November 10, 2023
Via
Benzinga
Qualcomm, Merck And 2 Other Stocks Insiders Are Selling
November 10, 2023
The Nasdaq 100 closed lower by more than 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.